BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598-609. [PMID: 30312513 DOI: 10.1111/liv.13986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, Álvarez-Mercado AI. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. Int J Mol Sci 2020;21:E8351. [PMID: 33171747 DOI: 10.3390/ijms21218351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
2 Rizowy GM, Poloni S, Colonetti K, Donis KC, Dobbler PT, Leistner-Segal S, Roesch LFW, Schwartz IVD. Is the gut microbiota dysbiotic in patients with classical homocystinuria? Biochimie 2020;173:3-11. [PMID: 32105814 DOI: 10.1016/j.biochi.2020.02.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Pan X, Kaminga AC, Liu A, Wen SW, Luo M, Luo J. Gut Microbiota, Glucose, Lipid, and Water-Electrolyte Metabolism in Children With Nonalcoholic Fatty Liver Disease. Front Cell Infect Microbiol 2021;11:683743. [PMID: 34778099 DOI: 10.3389/fcimb.2021.683743] [Reference Citation Analysis]
4 Mitten EK, Baffy G. Microbiota transplantation in portal hypertension: promises and pitfalls. Clin Sci (Lond) 2022;136:425-9. [PMID: 35333331 DOI: 10.1042/CS20220029] [Reference Citation Analysis]
5 Nicoletti A, Ponziani FR, Biolato M, Valenza V, Marrone G, Sganga G, Gasbarrini A, Miele L, Grieco A. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol 2019; 25(33): 4814-4834 [PMID: 31543676 DOI: 10.3748/wjg.v25.i33.4814] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
6 Altajar S, Baffy G. Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 2020;8:414-23. [PMID: 33447525 DOI: 10.14218/JCTH.2020.00065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Minaya DM, Turlej A, Joshi A, Nagy T, Weinstein N, DiLorenzo P, Hajnal A, Czaja K. Consumption of a high energy density diet triggers microbiota dysbiosis, hepatic lipidosis, and microglia activation in the nucleus of the solitary tract in rats. Nutr Diabetes 2020;10:20. [PMID: 32518225 DOI: 10.1038/s41387-020-0119-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
8 Wang T, Huang S, Wu C, Wang N, Zhang R, Wang M, Mao D. Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine. Evid Based Complement Alternat Med 2021;2021:6682581. [PMID: 33976705 DOI: 10.1155/2021/6682581] [Reference Citation Analysis]
9 Kong CY, Li ZM, Mao YQ, Chen HL, Hu W, Han B, Wang LS. Probiotic yogurt blunts the increase of blood pressure in spontaneously hypertensive rats via remodeling of the gut microbiota. Food Funct 2021;12:9773-83. [PMID: 34494630 DOI: 10.1039/d1fo01836a] [Reference Citation Analysis]
10 Chen J, Ding X, Wu R, Tong B, Zhao L, Lv H, Meng X, Liu Y, Ren B, Li J, Jian T, Li W. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition. J Agric Food Chem 2021;69:14176-91. [PMID: 34783554 DOI: 10.1021/acs.jafc.1c05596] [Reference Citation Analysis]
11 Zhang Q, Gao F, Yang X, Hu Y, Liu Y, Hou Y, Li Y, Zhu B, Niu S, Huang Y, Wang X. Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy.Med Sci Monit. 2020;26:e924040. [PMID: 32769964 DOI: 10.12659/MSM.924040] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Ryou M, Stylopoulos N, Baffy G. Nonalcoholic fatty liver disease and portal hypertension. Explor Med 2020;1:149-69. [PMID: 32685936 DOI: 10.37349/emed.2020.00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Liu Q, Liu S, Chen L, Zhao Z, Du S, Dong Q, Xin Y, Xuan S. Role and effective therapeutic target of gut microbiota in NAFLD/NASH. Exp Ther Med 2019;18:1935-44. [PMID: 31410156 DOI: 10.3892/etm.2019.7781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Huang HC, Tsai MH, Chang CC, Pun CK, Huang YH, Hou MC, Lee FY, Hsu SJ. Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats. Clin Sci (Lond) 2021;135:2709-28. [PMID: 34870313 DOI: 10.1042/CS20210602] [Reference Citation Analysis]
15 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
16 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Reference Citation Analysis]